A Phase 1 Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors and Determination of Tumor Receptor Occupancy by U3-1287.
Phase of Trial: Phase I
Latest Information Update: 19 Dec 2013
At a glance
- Drugs Patritumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 11 Jun 2013 Planned number of patients changed from 17 to 25 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 May 2012 Actual initiation date (April 2012) added as reported by ClinicalTrials.gov.